Literature DB >> 24071885

Outcome of patients with interstitial lung disease admitted to the intensive care unit.

A Vial-Dupuy1, O Sanchez, B Douvry, L Guetta, K Juvin, D Wermert, E Guérot, D Israël-Biet.   

Abstract

INTRODUCTION: The outcome of acute respiratory failure (ARF) affecting patients with various interstitial lung diseases (ILD) is poorly defined particularly in those with drug-induced ILD (DI-ILD). We investigated this issue focusing on fibrosing idiopathic interstitial pneumonitis (FIIP) and DI-ILD.
METHODS: We carried out a retrospective study of patients with ILD admitted in a single center ICU. The primary end-point was in-hospital mortality.
RESULTS: We included 72 subjects who fell into 3 diagnostic groups: DI-ILD (n=20), FIIP (n=28) and miscellaneous (M-ILD) (n=24). In-hospital mortality rates were 40% (n=8/20), 68% (n=19/28), and 25% (n=6/24) for DI-ILD, FIIP and M-ILD, respectively, (p=0.006). It reached, 64% (n=7/11), 100% (n=17/17) and 60% (n=6/10), respectively, in subjects on mechanical ventilation (p=0.007). In multivariate analysis, the need for mechanical ventilation (OR= 35; [95% CI, 5-255]), the type of ILD (FIIP vs miscellaneous) (OR=22; [95% CI, 3-147]) and high-dose steroids during ICU stay (OR=0.19; [95% CI, 0.04-0.99]) were independent determinants of in-hospital mortality.
CONCLUSION: This study, while confirming the poor prognosis of FIIP patients in ICU, highlights the better prognosis of DI-ILD and M-ILD even though severity criteria on admission are similar in these 3 groups. These data impact on the management of these patients in ICU in whom a proper diagnostic of the underlying condition is crucial.

Entities:  

Mesh:

Year:  2013        PMID: 24071885

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  7 in total

1.  [Acute on chronic respiratory failure in interstitial pneumonias].

Authors:  M Westhoff
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-08-16       Impact factor: 0.840

2.  Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease.

Authors:  Whitney D Gannon; David J Lederer; Mauer Biscotti; Azka Javaid; Nina M Patel; Daniel Brodie; Matthew Bacchetta; Matthew R Baldwin
Journal:  Chest       Date:  2018-01-17       Impact factor: 9.410

Review 3.  Drug-Induced Interstitial Lung Disease: A Systematic Review.

Authors:  Sarah Skeoch; Nicholas Weatherley; Andrew J Swift; Alexander Oldroyd; Christopher Johns; Conal Hayton; Alessandro Giollo; James M Wild; John C Waterton; Maya Buch; Kim Linton; Ian N Bruce; Colm Leonard; Stephen Bianchi; Nazia Chaudhuri
Journal:  J Clin Med       Date:  2018-10-15       Impact factor: 4.241

4.  Acute respiratory failure due to diffuse parenchymal lung diseases in a respiratory intensive care unit of North India.

Authors:  Inderpaul Singh Sehgal; Ritesh Agarwal; Sahajal Dhooria; Kuruswamy Thurai Prasad; Ashutosh N Aggarwal; Digambar Behera
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-09       Impact factor: 0.670

5.  Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.

Authors:  Johanna P van Gemert; Inge A H van den Berk; Esther J Nossent; Leo M A Heunks; Rene E Jonkers; Alexander P Vlaar; Peter I Bonta
Journal:  BMC Pulm Med       Date:  2021-07-28       Impact factor: 3.317

6.  Outcome and prognostic factors of interstitial lung disease patients with acute respiratory failure in the intensive care unit.

Authors:  Wei-Ling Lain; Shi-Chuan Chang; Wei-Chih Chen
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

7.  Aetiology and prognostic risk factors of mortality in patients with pneumonia receiving glucocorticoids alone or glucocorticoids and other immunosuppressants: a retrospective cohort study.

Authors:  Lijuan Li; Steven H Hsu; Xiaoying Gu; Shan Jiang; Lianhan Shang; Guolei Sun; Lingxiao Sun; Li Zhang; Chuan Wang; Yali Ren; Jinxiang Wang; Jianliang Pan; Jiangbo Liu; Cao Bin
Journal:  BMJ Open       Date:  2020-10-27       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.